Sugi Predict

Sugi Predict / Compounds / SCHEMBL3379207

SCHEMBL3379207

SCHEMBL3379207

CCOC(=O)Cc1nc2cc(N(C)C)ccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.64
▸ CHEK1 O14757 1/20 0.50
▸ MAPT P10636 4/20 0.49
▸ ALDH1A1 P00352 5/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ SIRT2 Q8IXJ6 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ LMNA P02545 3/20 0.41
▸ AKT1 P31749 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ELANE P08246 1/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ CACNA1G O43497 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ PAK4 O96013 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379211 0.90 HSD17B10 (0.64) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL3379876 0.87 HSD17B10 (0.58) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL3840417 0.84 HSD17B10 (0.71) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL3381341 0.83 HSD17B10 (0.62) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL12940747 0.82 HSD17B10 (0.67) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL7357580 0.82 HSD17B10 (0.67) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL3383858 0.81 HSD17B10 (0.66) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL38661615 0.81 HSD17B10 (0.66) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL7481256 0.80 HSD17B10 (0.64) HSD17B10CHEK1MAPTALDH1A1KDM4E
SCHEMBL7087108 0.79 HSD17B10 (0.57) HSD17B10CHEK1MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573079-A2 Benzimidazole quinolinones and uses thereof Novartis Vaccines and Diagnostics, Inc. (US) 2013-03-27 — — EP disclosed
EP-1497287-B1 Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-11-24 — — EP disclosed
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 — — US disclosed
US-20100184754-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-07-22 — — US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 — — US disclosed
EP-1313734-B1 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-11-11 — — EP disclosed
US-7598268-B2 Quinolinone derivatives NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-10-06 — — US disclosed
EP-1539754-A4 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-02-25 — — EP disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 — — US disclosed
US-7368459-B2 Heterocyclic compounds CHIRON CORPORATION (US) 2008-05-06 — — US disclosed
WO-2003087095-A1 QUINOLINONE DERIVATIVES CHIRON CORPORATION (US) 2003-10-23 — — WO disclosed
US-20030158224-A1 Quinolinone derivatives CHIRON CORPORATION 2003-08-21 — — US disclosed
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 — — US disclosed
EP-1317442-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
EP-1313734-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2003-05-28 — — EP disclosed
US-20030028018-A1 Quinolinone derivatives CHIRON COPORATION 2003-02-06 — — US disclosed
US-20020107392-A1 Quinolinone derivatives NOVARTIS AG (CH) 2002-08-08 — — US disclosed
US-20020103230-A1 Heterocyclic compounds CHIRON CORPORATION 2002-08-01 — — US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 — — WO disclosed
WO-2002018383-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2002-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103230-A1 Heterocyclic compounds SLCO2A1, SLCO1B1, SLCO2B1 HSD17B10 793/4885CHEK1 4225/4885MAPT 3261/4885
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 HSD17B10 754/4885CHEK1 2358/4885MAPT 575/4885
US-20030028018-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885
US-20030158224-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885
US-20020107392-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885
US-20100184754-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 HSD17B10 498/4885CHEK1 3447/4885MAPT 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.